IP Group

Ankere is striving to develop transformative therapies based on excellent science that will enable people to live long and healthy lives.

Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.

Aptatek Biosciences Inc is a Princeton, New Jersey-based company that develops portable disease management devices specifically for individuals with Phenylketonuria (PKU). Their innovative products utilize sensor technology to monitor phenylalanine levels in real-time, allowing for immediate blood analysis and reporting. These Bluetooth-enabled devices facilitate the detection of small molecules and biomarkers, enabling patients to make timely dietary adjustments to maintain their phenylalanine levels within clinical target ranges. By providing healthcare providers with tools to enhance patient compliance and overall wellness, Aptatek Biosciences aims to improve the quality of life for those affected by PKU.

Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the drug development process through an asset-centric research and development model. The company advances a diverse portfolio of validated programs, each managed by a dedicated subsidiary and backed by a centralized infrastructure and experienced management team. Among its pipeline assets are SerpinPC, targeting Hemophilia A and B, LB101 for solid tumors, ORX750 for narcolepsy type 1 and other sleep disorders, and MGX292 for pulmonary arterial hypertension. Additionally, Centessa is developing an undisclosed asset for solid tumors.

MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.

Kira Biotech Pty Ltd is an Australian biotechnology company focused on developing innovative immunomodulatory compounds for treating immune system disorders, including rheumatoid arthritis, systemic lupus erythematosus, and type 1 diabetes. Established in 2017 and based in Brisbane, Kira Biotech is advancing its lead candidate, KB312, a first-in-class selective monoclonal antibody designed to target activated immune cells. This approach aims to restore immune system balance by inducing tolerance. The company has secured venture capital funding and is currently progressing KB312 through preclinical development and phase 1 clinical trials, guided by a team of experts in drug development, including prominent US-based rheumatologist and immunologist Dr. Dan Baker.

STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.

Aqdot Limited, founded in 2012 and located in Cambridge, United Kingdom, specializes in the manufacturing of smart microcapsules with customizable properties tailored for various industries. The company has developed a unique one-step shrink-wrap approach that combines emulsion technology and supramolecular chemistry, simplifying the microencapsulation process. This innovative technology promotes energy and raw material efficiency, resulting in reduced energy consumption and waste production. Aqdot's microcapsules have potential applications across multiple sectors, including encapsulating enzymes for laundry detergents and fertilizers in agriculture. The microencapsulation market is substantial, with established uses in household and personal care products, food, and agrochemicals.

Genomics PLC is focused on advancing the use of genomic data to transform healthcare. The company develops algorithms and software solutions that facilitate the analysis of large genomic and phenotypic datasets, aimed at understanding human biology and improving disease diagnosis and treatment. Its offerings serve a diverse range of clients, including governments, healthcare providers, pharmaceutical companies, and research laboratories. By providing tools that enhance the accuracy of genetic analysis, Genomics PLC helps de-risk the drug development process and enables clinicians to better identify individuals at risk for specific diseases. Founded in 2014 and based in Oxford, United Kingdom, the company aims to set standards in genomic data application, ultimately benefiting organizations and patients alike through innovative healthcare solutions.

Genomics PLC is focused on advancing the use of genomic data to transform healthcare. The company develops algorithms and software solutions that facilitate the analysis of large genomic and phenotypic datasets, aimed at understanding human biology and improving disease diagnosis and treatment. Its offerings serve a diverse range of clients, including governments, healthcare providers, pharmaceutical companies, and research laboratories. By providing tools that enhance the accuracy of genetic analysis, Genomics PLC helps de-risk the drug development process and enables clinicians to better identify individuals at risk for specific diseases. Founded in 2014 and based in Oxford, United Kingdom, the company aims to set standards in genomic data application, ultimately benefiting organizations and patients alike through innovative healthcare solutions.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.

Spirea Ltd. operates as a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.

Lorem Therapeutics is focusing on development early stage therapeutics in the phase between initial drug discovery and when a treatment begins review by the FDA for status as an Investigational New Drug. The company will use the funding “to accelerate and enhance our drug discovery efforts around critical cancer indications,” Slusher said in a statement.

Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Uniphy is an electronic company that enables intuitive free-form Touch Interfaces that are beautiful, robust and economic. Through continuous innovation in hardware, software, opto-mechanical design and material engineering, UniPhy delivers solutions and support for intuitive freeform touch Interfaces that are differtiated in terms of beauty, robustness, time to market and affordability.

Avacta Group is a UK-based company that specializes in the development and provision of reagents and therapeutics utilizing its proprietary Affimer technology for applications in diagnostics and research. The company operates across three primary segments: Diagnostics, Therapeutics, and Animal Health. It focuses on creating custom Affimer proteins for diagnostic assays and customer products, as well as developing innovative cancer immunotherapies. Avacta Group also offers tools and contract services to facilitate the diagnosis and treatment of animal health conditions. The company has established various collaborations and partnerships, including research agreements with Moderna Therapeutics and co-development projects with other organizations to advance Affimer drug conjugate therapies and rapid diagnostic tests. Founded in 2003 and headquartered in Wetherby, Avacta Group plays a significant role in the life science market, providing solutions from drug discovery to clinical diagnostics.

Genomics PLC is focused on advancing the use of genomic data to transform healthcare. The company develops algorithms and software solutions that facilitate the analysis of large genomic and phenotypic datasets, aimed at understanding human biology and improving disease diagnosis and treatment. Its offerings serve a diverse range of clients, including governments, healthcare providers, pharmaceutical companies, and research laboratories. By providing tools that enhance the accuracy of genetic analysis, Genomics PLC helps de-risk the drug development process and enables clinicians to better identify individuals at risk for specific diseases. Founded in 2014 and based in Oxford, United Kingdom, the company aims to set standards in genomic data application, ultimately benefiting organizations and patients alike through innovative healthcare solutions.

Diurnal Group plc is a specialty pharmaceutical company based in Cardiff, United Kingdom, that focuses on developing hormone therapeutics for chronic endocrine conditions. The company offers Alkindi, a replacement therapy specifically designed for pediatric adrenal insufficiency in Europe. Diurnal is advancing its product pipeline with Chronocort, which has completed Phase III clinical trials for congenital adrenal hyperplasia and adrenal insufficiency. Additionally, its early-stage pipeline includes Native Oral Testosterone for hypogonadism, a siRNA therapy for adrenocorticotropin-dependent Cushing's syndrome, and a modified-release formulation of T3 for hypothyroidism. Incorporated in 2015, Diurnal aims to provide innovative, high-value therapeutics through proprietary formulations and physiological treatment approaches for rare and chronic diseases.

Genomics PLC is focused on advancing the use of genomic data to transform healthcare. The company develops algorithms and software solutions that facilitate the analysis of large genomic and phenotypic datasets, aimed at understanding human biology and improving disease diagnosis and treatment. Its offerings serve a diverse range of clients, including governments, healthcare providers, pharmaceutical companies, and research laboratories. By providing tools that enhance the accuracy of genetic analysis, Genomics PLC helps de-risk the drug development process and enables clinicians to better identify individuals at risk for specific diseases. Founded in 2014 and based in Oxford, United Kingdom, the company aims to set standards in genomic data application, ultimately benefiting organizations and patients alike through innovative healthcare solutions.

Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, that specializes in the development of innovative medicines for cancer. Established in 2005, the company focuses on designing and developing orally-active small molecule drugs aimed at targeting specific molecular pathways. Its notable products include KA2237, a dual-selective inhibitor of PI3K isoforms p110ß and p110d, designed for treating both hematological and solid tumors, and KA2507, an HDAC6 inhibitor intended for tumors expressing PD-L1. Karus Therapeutics aims to address unmet medical needs in oncology through its targeted therapeutic approaches.

Clyde Biosciences Ltd. specializes in developmental drug testing solutions, focusing on cardiac cell analysis to provide insights into drug mechanisms and toxicity. The company has developed cellOPTIQ, an optical action potential assay that helps clients assess the cardiotoxicity risk of new and existing drugs by evaluating their effects on human cells. Additionally, Clyde Biosciences offers XTENDSR, which allows for direct measurements of drug-induced changes in cardiac sarcoplasmic reticulum function. By delivering human-relevant cardiomyocyte functional data, the company aids pharmaceutical and biotechnology firms in mitigating risks during drug development. Founded in 2012 and based in Glasgow, United Kingdom, Clyde Biosciences serves clients both domestically and internationally.

Creating a new generation of biological therapeutics through advanced glycosylation technologies Glythera Limited is a young spin-out biotechnology company from the University of Bath with core expertise in protein/peptide functionalisation and glycosylation technologies, imparting improved pharmacokinetic properties to biological therapeutics. Glythera successfully raised its first round of investment in 2008, with research operations being conducted in dedicated laboratories situated on the campus of the University of Bath

Activiomics Ltd. specializes in biomarker technology and phosphoproteomics solutions, focusing on the identification and quantification of critical phosphorylation sites that play a vital role in cellular processes. The company's patented TIQUAS (Targeted In-depth QUAntification of cell Signalling) technology employs advanced, label-free mass spectrometry methods to analyze thousands of phosphorylation events from clinical tissue samples. This innovative approach allows for the direct correlation of proteins and phosphoproteins with disease progression and drug administration. By identifying novel biomarkers through these techniques, Activiomics aims to enhance the development of diagnostics and improve drug candidate profiling, ultimately contributing to advancements in personalized medicine and therapeutic strategies.

Crysalin Limited, founded in June 2007 and based in London, specializes in the research and development of crysalin lattice technology, which is derived from patented work initiated in 2002 at the Oxford University Laboratory of Molecular Biophysics. The company's core product, crysalins, is a protein-based nanotechnology that significantly enhances the determination of protein structures, particularly for challenging targets such as membrane proteins and soluble proteins with flexible regions. Crysalins enable the resolution of three-dimensional molecular structures using X-ray and electron microscopy techniques, where traditional methods have struggled. In addition to protein structure determination, crysalins hold potential applications in biosensor development and optoelectronics, showcasing the versatility and innovative capacity of the technology.

Creating a new generation of biological therapeutics through advanced glycosylation technologies Glythera Limited is a young spin-out biotechnology company from the University of Bath with core expertise in protein/peptide functionalisation and glycosylation technologies, imparting improved pharmacokinetic properties to biological therapeutics. Glythera successfully raised its first round of investment in 2008, with research operations being conducted in dedicated laboratories situated on the campus of the University of Bath

Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, that specializes in the development of innovative medicines for cancer. Established in 2005, the company focuses on designing and developing orally-active small molecule drugs aimed at targeting specific molecular pathways. Its notable products include KA2237, a dual-selective inhibitor of PI3K isoforms p110ß and p110d, designed for treating both hematological and solid tumors, and KA2507, an HDAC6 inhibitor intended for tumors expressing PD-L1. Karus Therapeutics aims to address unmet medical needs in oncology through its targeted therapeutic approaches.

TheraGenetics was spun out of King's College London in April 2006. Their technology is based upon pharmacogenetics; the study of genetic factors involved in influencing an individual's response to drug treatments. The strong foundation of TheraGenetics stems from the founding team's long commitment to pharmacogenetics that has situated us at the cutting edge of personalised medicine. Under the umbrella of the Institute of Psychiatry at King's College London, the founding team translated 15 years of research into the commercial world by developing the first pharmacogenetic test for response prediction in psychiatry. In 2005, this test which focuses on the schizophrenia treatment clozapine, was successfully licensed by King's College London to a major UK laboratory who have successfully brought the test to market in 2006. Based on this achievement and the overwhelming enthusiasm for personalised medicine solutions, King's College London, the academic founders and the London based venture firm IPGroup PLC launched TheraGenetics in April 2006. TheraGenetics unique knowledge and experience in CNS disorders extends from the bench to the bedside. The ultimate clinical utility has been a priority consideration at all stages of their test development; their clinical team knows what is required at the patient care interface and they develop tests accordingly. The TheraGenetic's team has a threshold of knowledge and experience spanning the whole test development process that is now allowing us to rapidly advance their work in the field of pharmacogenetic response prediction.

Oxtox is developing Drugsensorâ„¢, a device that uses novel and cost-effective technology to rapidly detect whether a person is currently 'under the influence' of specific drugs, all with a minimum of inconvenience.

Cerogenix is a drug discovery and diagnostics.